Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb5574 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | XmAb5574 |
| Name | Type | Description |
|---|---|---|
| XmAb5574 | BIOLOGICAL | Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22) |
Inclusion Criteria: * relapsed or refractory CLL/SLL * at least 18 years of age * able to receive outpatient treatment and follow-up at the treating institution * completed all CLL therapies \> 4 weeks prior to first study dose Exclusion Criteria: * previously treated with an anti-CD19 antibody t...
XmAb5574 is an investigational monoclonal antibody being studied for the treatment of Chronic Lymphocytic Leukemia (CLL). It is being developed by Xencor, Inc. (XNCR) and is currently in Phase 1 clinical development. The drug is intended for patients with CLL, a type of cancer that affects the blood and bone marrow.
XmAb5574 is being developed by Xencor, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol XNCR. Xencor is responsible for the research and clinical development of this investigational monoclonal antibody for the treatment of Chronic Lymphocytic Leukemia.
XmAb5574 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and tolerability. The drug is being studied for the treatment of Chronic Lymphocytic Leukemia.
XmAb5574 has been studied in one clinical trial with the identifier NCT01161511. This Phase 1 trial, titled 'Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia,' has been completed. The study enrolled 27 participants with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the United States.
XmAb5574 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed clinical trial (NCT01161511) was designed to assess the safety and tolerability of the drug in patients with Chronic Lymphocytic Leukemia, but it has not yet received regulatory approval.